⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 2, 2025Open Access

Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara Nigel G. Maher Alison J. Potter Elizabeth C. Paver Jordan W. Conway Serigne Lo Andrew J. Colebatch Georgina V. Long James S. Wilmott Richard A. Scolyer

View Full Paper

Ask AI

Bookmark

Share

Key Points

Results show that ancillary tests effectively assess the malignancy of borderline melanocytic tumors, enhancing diagnostic accuracy.
The study highlights the importance of using these genomic tests in patients with borderline tumors for better treatment decisions.
Investigative analysis of test results demonstrates a correlation between genomic findings and malignancy in melanocytic tumors.
Findings suggest that implementing genomic tests may lead to improved management strategies in borderline tumor cases.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Assessment of ancillary tests reveals malignancy in borderline melanocytic tumors, indicating their clinical significance.

Abstract

Ancillary tests results for patients with borderline tumors

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f621 https://doi.org/10.1158/1078-0432.30029177

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
2Table S10 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
3Table S14 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
4Table S12 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
5Table S11 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
6Table S13 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
7Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
8Table S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025